公开(公告)号：US20150283198A1

公开(公告)日：2015-10-08

申请号：US14676370

申请日：2015-04-01

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang

IPC: A61K38/06 ,  A61K31/7072 ,  A61K38/05

CPC classification number: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K38/05 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明的特征在于用于治疗HCV的无干扰素治疗。 优选地，治疗超过较短的治疗持续时间，例如不超过12周。 在一个方面，治疗包括向具有HCV感染的受试者施用至少两种直接作用的抗病毒剂，其中所述治疗持续12周，并且不包括施用干扰素或利巴韦林，并且所述至少两种直接作用的抗病毒剂包含 （a）化合物1或其药学上可接受的盐和（b）化合物2或其药学上可接受的盐。

公开(公告)号：US20150174194A1

公开(公告)日：2015-06-25

申请号：US14574654

申请日：2014-12-18

Applicant: AbbVie Inc.

Inventor： Barry M. Bernstein ,  Eoin Coakley ,  Regis A. Vilchez

IPC: A61K38/07 ,  A61K38/06 ,  A61K31/513 ,  A61K31/427

CPC classification number: A61K38/07 ,  A61K31/427 ,  A61K31/4965 ,  A61K31/513 ,  A61K31/7056 ,  A61K38/06 ,  A61K2300/00

Abstract: This application features interferon-free therapies for the prevention or treatment of HCV infection in liver transplant recipient. In one aspect, the treatment comprises administering a DAA combination to a liver transplant recipient after liver transplantation, wherein the DAA combination comprises Compound 1, ritonavir, Compound 2 and Compound 4.

Abstract translation: 该应用的特点是用于预防或治疗肝脏移植受体中HCV感染的无干扰素治疗。 一方面，治疗包括在肝移植后向肝移植受体施用DAA组合，其中DAA组合包含化合物1，利托那韦，化合物2和化合物4。

公开(公告)号：US08853176B2

公开(公告)日：2014-10-07

申请号：US13656024

申请日：2012-10-19

Applicant: AbbVie Inc.

Inventor： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

IPC: A01N43/04 ,  A61K31/70 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/4178 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/4709 ,  A61K31/4025

CPC classification number: A61K38/07 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/439 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/06 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

公开(公告)号：US20140275099A1

公开(公告)日：2014-09-18

申请号：US14210870

申请日：2014-03-14

Applicant: AbbVie Inc.

Inventor： Barry M. Bernstein ,  Sandeep Dutta ,  Wei Liu ,  Thomas J. Podsadecki ,  Andrew L. Campbell ,  Rajeev M. Menon ,  Chih-Wei Lin ,  Tianli Wang ,  Walid M. Awni

IPC: A61K31/4985 ,  A61K31/454

CPC classification number: A61K31/4985 ,  A61K31/454 ,  A61K31/498

Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明的特征在于用于治疗HCV的干扰素和不含利巴韦林的疗法。 优选地，治疗超过较短的治疗持续时间，例如不超过12周。 在一个方面，治疗包括向没有干扰素和利巴韦林的至少两种直接作用的抗病毒剂施用HCV感染的受试者，其中所述治疗持续12周，并且所述至少两种直接作用的抗病毒剂包含（a）化合物1或 其药学上可接受的盐和（b）化合物2或其药学上可接受的盐。

公开(公告)号：US20140274934A1

公开(公告)日：2014-09-18

申请号：US14210858

申请日：2014-03-14

Applicant: AbbVie Inc.

Inventor： Barry M. Bernstein ,  Sandeep Dutta ,  Wei Liu ,  Thomas J. Podsadecki ,  Andrew L. Campbell ,  Rajeev M. Menon ,  Chih-Wei Lin ,  Tianli Wang ,  Walid M. Awni

IPC: A61K31/7056 ,  A61K31/454 ,  A61K31/4985

CPC classification number: A61K31/7056 ,  A61K31/454 ,  A61K31/4985 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明的特征在于用于治疗HCV的无干扰素治疗。 优选地，治疗超过较短的治疗持续时间，例如不超过12周。 一方面，治疗包括给具有HCV感染的受试者施用至少两种直接作用的抗病毒剂和利巴韦林，其中所述治疗持续12周，并且不包括施用干扰素，并且所述至少两种直接作用的抗病毒剂包含 a）化合物1或其药学上可接受的盐和（b）化合物2或其药学上可接受的盐。

公开(公告)号：US20130102557A1

公开(公告)日：2013-04-25

申请号：US13656024

申请日：2012-10-19

Applicant: AbbVie Inc.

Inventor： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

IPC: A61K31/7056 ,  A61P31/14

CPC classification number: A61K38/07 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/439 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/06 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

公开(公告)号：US20230385268A1

公开(公告)日：2023-11-30

申请号：US18232896

申请日：2023-08-11

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Tianli Wang

IPC: G06F16/23 ,  G06F7/00 ,  G06F16/215 ,  G06F16/25

CPC classification number: G06F16/2365 ,  G06F7/00 ,  G06F16/215 ,  G06F16/2379 ,  G06F16/252

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20190336565A1

公开(公告)日：2019-11-07

申请号：US16405029

申请日：2019-05-07

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang ,  Sven Mensing

IPC: A61K38/06 ,  A61K31/498 ,  A61K31/7072 ,  A61K38/05 ,  A61K31/454

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US10286029B2

公开(公告)日：2019-05-14

申请号：US14676370

申请日：2015-04-01

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang ,  Sven Mensing

IPC: A61K38/06 ,  A61K31/7072 ,  A61K38/05 ,  A61K31/454 ,  A61K31/498

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20180177778A1

公开(公告)日：2018-06-28

申请号：US15738762

申请日：2016-06-28

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Tolga Baykal ,  Barry M. Bernstein ,  Scott c. Brun ,  Daniel E. Cohen ,  Emily O. Dumas ,  Sandeep Dutta ,  Amit Khatri ,  Cheri E. Klein ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Lino X Rodrigues Jr. ,  Regis A. Vilchez

IPC: A61K31/497 ,  A61P31/14 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/7056

CPC classification number: A61K31/497 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/7056 ,  A61P31/14 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for treating Hepatitis C Virus (HCV) genotypes 1b, 2, 3 or 4. In one aspect, the therapies comprises administering Compound 1 (Paritaprevir), Ritonavir, and Compound 2 (Ombitasvir) to a subject infected with HCV genotype 1b or 4, wherein the therapies do not include the administration of any interferon, and the therapies last from 8 to 12 weeks. Preferably, the therapies do not include the administration of any ribavirin.